ViewMind Inc.

ViewMind develops digital cognitive biomarkers to accurately measure brain health and diagnose neurocognitive disorders. ViewMind’s technology combines VR, eye-tracking and AI, and has been independently validated by Tier 1 pharmaceutical companies and leading hospital facilities in randomized controlled trials. The initial commercial focus is improving outcomes for patients with multiple sclerosis, a group who has unmet clinical needs ViewMind can target.